论文部分内容阅读
在人体卵巢里,垂体催乳激素(PRL)的生理作用尚未被充分认识。为了确定PRL是否影响雌激素在卵巢里的生物合成,丹麦奥登塞大学医院妇产科观察了在单用HMG和同时并用催乳激素抑制剂溴隐亭治疗6名闭经妇女的20个治疗周期中雌激素的反应。 在观察的6名闭经妇女中,5名加用溴隐亭者比单独应用HMG治疗者尿中雌激素排泄物高79％。因为溴隐亭和HMG治疗是同时开始的,LH和FSH的水平未受到增加溴隐亭的影响,所以应该推测这个效果与溴隐亭的中枢性多巴胺能效应降低了血清PRL水平有关。 病人1、2、3和5血清PRL水平正常。溴隐亭与HMG联合给药时,增加了雌激素的反应。这个反应表明,溴隐亭对具有正常血
In the human ovary, the physiological role of pituitary prolactin (PRL) has not been fully understood. To determine whether PRL affects the biosynthesis of estrogen in the ovary, the Department of Obstetrics and Gynecology, University Hospital of Odense, Denmark, examined the effect of treatment with HMG and concurrent bromocriptine, a prolactin inhibitor, on 20 cycles of treatment of 6 menopausal women Estrogen response. Of the 6 menopausal women observed, 5 were more likely to have estrogen excretion in the urine than 79% of those given HMG alone. Because bromocriptine and HMG treatment are initiated simultaneously, the levels of LH and FSH are not affected by increased bromocriptine, so it should be speculated that this effect is related to a decrease in serum PRL levels with central dopaminergic effects of bromocriptine. Patient 1, 2, 3 and 5 serum PRL levels were normal. When bromocriptine is administered in combination with HMG, the estrogen response is increased. This reaction shows that bromocriptine has normal blood